Shanghai Junshi Biosciences Co Ltd (Junshi Biosciences) is a biopharmaceutical company that discovers, develops and commercializes drugs for infectious diseases, oncology, metabolic, auto-immunity and neurologic indications. It is focused on investigating JS001 antibody against various malignant tumors; JS003, JS006, and JS201 to treat solid tumors; JS004 for melanoma, hodgkin lymphoma and lung carcinoma; JS101 for the treatment of breast cancer; JS108 for pancreatic, triple-negative breast cancer, small cell lung cancer. The company is also evaluating JS002 against hyperlipidaemia; JS103 for hyperuricacidemia and gout disease; UPB1211 to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS010 for migraine; and JS016 against COVID-19. It operates research and development centers in California and Maryland, the US. Junshi Biosciences is headquartered in Shanghai, China.
Headquarters
China
Address
15F, Building 7, Crystal Plaza, No.6, Lane 100, Pingjiaqiao Road, Shanghai, 201203
Website
www.junshipharma.com
Telephone
86 21 61058800
No of Employees
2,568
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1877 (HKG)
Revenue (2022)
$212.4M
3.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
4.4%
(2022 vs 2021)
Market Cap*
$3.0B
Net Profit Margin (2022)
XYZ
7.5%
(2022 vs 2021)
* As of and is in US$
Shanghai Junshi Biosciences Co Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Pipeline | Research and Development |
| JS001: | Therapies |
| Malignant Tumors | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In April, the company secured approval from the National Medical Products Administration for toripalimab. |
| 2024 | Regulatory Approval | In February, the company received approval from the Singapore Health Sciences Authority for toripalimab for the initial treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. |
| 2024 | Contracts/Agreements | In January, the company entered into a Technology Development Contract with Shanghai Allink, under which Shanghai Allink undertook a research and development project for cell line development and production of drug substances and preparations. |
Competitor Comparison
| Key Parameters | Shanghai Junshi Biosciences Co Ltd | InnoCare Pharma Ltd | Sino Biological Inc | Ascletis Pharma Inc | China Pharma Holdings Inc |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Beijing | Beijing | Hangzhou | Haikou |
| State/Province | Shanghai | Beijing | Beijing | Zhejiang | Hainan |
| No. of Employees | 2,568 | 1,072 | 913 | 219 | 231 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Xiong Jun | Chairman | Executive Board | 2018 | 47 |
| Li Ning | Vice Chairman | Executive Board | 2024 | 62 |
| Sheng Yao | Senior Vice President; Director; Deputy General Manager | Executive Board | 2018 | 48 |
| Zou Jianjun | Director; Deputy General Manager | Executive Board | 2022 | 53 |
| Wang Gang | Director | Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward